CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 82 enrolled
Drug / intervention
sodium valproatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00870688
NCT00870688N/ACompleted

Non Interventional Trial of Valproate Sustained Release Minitablets Once Daily in the Evening

Desitin Arzneimittel GmbH·observational·Posted Mar 27, 2009·Updated May 20, 2009

In Brief

An observational study evaluating sodium valproate for Epilepsy. Completed, enrolled 82 participants.

Detailed Summary

Valproate is the first line therapy in primary generalized seizures. The applied drug contains sodium valproate in sustained release minitablets. As a multiple unit dosage form these can be easily swallowed and taken independent from meals. A simple dosage scheme like valproate sustained release minitablets once daily in the evening should improve the compliance and likely the seizure situation of the patients. The data of this non interventional trial were directly extracted from the physician's electronic patient database. The observational period was 7 weeks compared to a retrospective period 7 weeks before start of the study.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 27, 2009
Enrollment StartJan 1, 2005
Primary CompletionApr 1, 2006
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.3 years ago

Interventions

sodium valproatedrug

valproate sustained release minitablets, once daily.